Stock market analyst Kunal Saraogi has maintained 'buy' rating on Ranbaxy Laboratories Ltd stock with short term target of Rs 525.

According to analyst, the interested investors can buy the stock with strict stop loss of Rs 495.

The stock of the company, on Sep 01, closed at Rs 497.75 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 538 and a low of Rs 317 on BSE.

Current EPS & P/E ratio stood at 27.74 and 18.34 respectively.

Ranbaxy Laboratories Ltd's wholly owned arm, Ranbaxy (South Africa) Pvt Ltd, has made announcement about the launching of its new high-tech production facility, Be-Tabs Pharmaceuticals Manufacturing Plant, at Roodepoort, Johannesburg, South Africa.

According to reports, Anand Sharma, Minister for Commerce and Industry, kicked off Be-Tabs Pharmaceuticals Manufacturing Plant in front of the Indian High Commissioner, Virendra Gupta and delegates from the South African division of Trade and Industry.

The reports added that this will be the company's second manufacturing plant in the South African market and the third in the African continent.

Moreover, Ranbaxy Labs Ltd has settled down its patent clash with Swiss major Roche for the latter's medication valganciclovir sold under the trade nameValcyte.